Dianne C. Whitfield Sells 2,137 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Stock

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Get Free Report) insider Dianne C. Whitfield sold 2,137 shares of the firm's stock in a transaction on Thursday, March 20th. The stock was sold at an average price of $50.11, for a total value of $107,085.07. Following the completion of the transaction, the insider now directly owns 46,355 shares in the company, valued at approximately $2,322,849.05. This represents a 4.41 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.

Tarsus Pharmaceuticals Price Performance

Shares of Tarsus Pharmaceuticals stock traded up $2.39 on Monday, hitting $52.36. 1,101,887 shares of the company traded hands, compared to its average volume of 643,190. Tarsus Pharmaceuticals, Inc. has a 52 week low of $20.08 and a 52 week high of $57.28. The business has a 50-day simple moving average of $48.59 and a 200 day simple moving average of $45.64. The company has a debt-to-equity ratio of 0.30, a quick ratio of 5.38 and a current ratio of 5.42. The stock has a market capitalization of $2.01 billion, a P/E ratio of -13.74 and a beta of 1.05.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last announced its quarterly earnings results on Tuesday, February 25th. The company reported ($0.60) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.68) by $0.08. Tarsus Pharmaceuticals had a negative net margin of 103.64% and a negative return on equity of 55.86%. The company had revenue of $66.41 million for the quarter, compared to the consensus estimate of $58.80 million. Research analysts expect that Tarsus Pharmaceuticals, Inc. will post -3.17 earnings per share for the current fiscal year.

Remove Ads

Analysts Set New Price Targets

A number of research analysts have recently weighed in on TARS shares. Oppenheimer lifted their price objective on Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the company an "outperform" rating in a research report on Wednesday, January 22nd. Barclays lowered their price target on shares of Tarsus Pharmaceuticals from $62.00 to $60.00 and set an "overweight" rating on the stock in a report on Wednesday, February 26th. HC Wainwright reissued a "buy" rating and issued a $73.00 price objective on shares of Tarsus Pharmaceuticals in a research note on Wednesday, February 26th. Jefferies Financial Group raised their price objective on shares of Tarsus Pharmaceuticals from $54.00 to $58.00 and gave the company a "buy" rating in a research report on Thursday, March 6th. Finally, Guggenheim reiterated a "buy" rating and issued a $78.00 price target (up previously from $75.00) on shares of Tarsus Pharmaceuticals in a research note on Monday, February 24th. One equities research analyst has rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus target price of $63.67.

Institutional Investors Weigh In On Tarsus Pharmaceuticals

Several large investors have recently made changes to their positions in TARS. Crowley Wealth Management Inc. purchased a new position in Tarsus Pharmaceuticals during the 4th quarter valued at approximately $25,000. GF Fund Management CO. LTD. purchased a new stake in shares of Tarsus Pharmaceuticals during the 4th quarter worth approximately $44,000. R Squared Ltd bought a new position in shares of Tarsus Pharmaceuticals during the 4th quarter valued at approximately $53,000. Quarry LP purchased a new position in shares of Tarsus Pharmaceuticals in the fourth quarter valued at $166,000. Finally, HighTower Advisors LLC bought a new stake in Tarsus Pharmaceuticals in the fourth quarter worth $207,000. 90.01% of the stock is owned by institutional investors.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.